Publications by authors named "Marion Fovet"
Objectives: The total psoas area index (TPI) is an emerging alternative to the total skeletal muscle area index as a prognostic factor but has never been evaluated in metastatic pancreatic cancer (mPC).
Methods: Areas were manually recorded, as previously described. Sex-specific cutoffs were identified by optimum stratification of TPI using log-rank χ2 statistic associated with mortality to define sarcopenic psoas.
Background & Aims: We investigated whether serum trough levels of vedolizumab, a humanized monoclonal antibody against integrin α4β7, during the induction phase of treatment can determine whether patients will need additional doses (optimization of therapy) within the first 6 months.
Methods: We conducted an observational study of 47 consecutive patients with Crohn's disease (CD; n = 31) or ulcerative colitis (UC; n = 16) who had not responded to 2 previous treatment regimens with antagonists of tumor necrosis factor and were starting therapy with vedolizumab at 2 hospitals in France, from June 2014 through April 2016. All patients were given a 300-mg infusion of vedolizumab at the start of the study, Week 2, Week 6, and then every 8 weeks; patients were also given corticosteroids during the first 4-6 weeks.
Prognosis of metastatic colorectal cancer has dramatically improved during these two last decades, through a better understanding of therapeutic goals and the development of news drugs such as biologics. The character resectable, potentially resectable or not resectable of colorectal cancer liver metastasis should be considered at baseline because it determines the systemic chemotherapy which will be conducted. Considering resectable metastasis, 6 courses of FOLFOX (5 fluoro-uracil + oxaliplatin) will be administered before and after surgery in the goal of "cleaning" the body from the potential micrometastasis.
View Article and Find Full Text PDF